The 2021 WHO classification of tumors of the central nervous system: an update on pediatric low‐grade gliomas and glioneuronal tumors

TA Bale, MK Rosenblum - Brain Pathology, 2022 - Wiley Online Library
The 2021 5th edition of the WHO Classification of Tumors of the Central Nervous System
reflects the discovery of genetic alterations underlying many central nervous system (CNS) …

Pediatric low-grade glioma in the era of molecular diagnostics

S Ryall, U Tabori, C Hawkins - Acta neuropathologica communications, 2020 - Springer
Low grade gliomas are the most frequent brain tumors in children and encompass a
spectrum of histologic entities which are currently assigned World Health Organisation …

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre …

J Fangusaro, A Onar-Thomas, TY Poussaint… - The lancet …, 2019 - thelancet.com
Background Paediatric low-grade glioma is the most common CNS tumour of childhood.
Although overall survival is good, disease often recurs. No single universally accepted …

Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas

A Lassaletta, M Zapotocky, M Mistry… - Journal of Clinical …, 2017 - ascopubs.org
Purpose BRAF V600E is a potentially highly targetable mutation detected in a subset of
pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group …

A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

S Perreault, V Larouche, U Tabori, C Hawkin, S Lippé… - BMC cancer, 2019 - Springer
Background Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in
children. Up to 50% will be refractory to conventional chemotherapy. It is now known that the …

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas

AJ Sievert, SS Lang, KL Boucher… - Proceedings of the …, 2013 - National Acad Sciences
Astrocytomas are the most common type of brain tumors in children. Activated BRAF protein
kinase mutations are characteristic of pediatric astrocytomas with KIAA1549-BRAF fusion …

Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma

H Cin, C Meyer, R Herr, WG Janzarik, S Lambert… - Acta …, 2011 - Springer
Activation of the MAPK signaling pathway has been shown to be a unifying molecular
feature in pilocytic astrocytoma (PA). Genetically, tandem duplications at chromosome 7q34 …

Optic pathway gliomas in neurofibromatosis type 1: an update: surveillance, treatment indications, and biomarkers of vision

PMK de Blank, MJ Fisher, GT Liu… - Journal of Neuro …, 2017 - journals.lww.com
Optic pathway gliomas (OPGs) occur in 15%–20% of children with neurofibromatosis type 1
(NF1), leading to visual deficits in fewer than half of these individuals. The goal of …

MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification

H Liu, T Tang - Scientific Reports, 2023 - nature.com
An early diagnosis and precise prognosis are critical for the treatment of glioma. The
mitogen‑activated protein kinase (MAPK) signaling pathway potentially affects glioma, but …

TRK fusion cancers in children: a clinical review and recommendations for screening

CM Albert, JL Davis, N Federman… - Journal of Clinical …, 2019 - ascopubs.org
Chromosomal translocations involving the NTRK1, NTRK2, and NTRK3 genes (TRK
fusions), which encode the neurotrophin tyrosine kinase receptors TRKA, TRKB, and TRKC …